Substance (Drug) Abuse - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Substance (Drug) Abuse - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Substance (Drug) Abuse - Pipeline Review, H1 2015', provides an overview of the Substance (Drug) Abuse's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Substance (Drug) Abuse, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Substance (Drug) Abuse and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Substance (Drug) Abuse
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Substance (Drug) Abuse and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Substance (Drug) Abuse products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Substance (Drug) Abuse pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Substance (Drug) Abuse
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Substance (Drug) Abuse pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Substance (Drug) Abuse Overview 7
Therapeutics Development 8
Pipeline Products for Substance (Drug) Abuse - Overview 8
Pipeline Products for Substance (Drug) Abuse - Comparative Analysis 9
Substance (Drug) Abuse - Therapeutics under Development by Companies 10
Substance (Drug) Abuse - Therapeutics under Investigation by Universities/Institutes 11
Substance (Drug) Abuse - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Substance (Drug) Abuse - Products under Development by Companies 14
Substance (Drug) Abuse - Products under Investigation by Universities/Institutes 15
Substance (Drug) Abuse - Companies Involved in Therapeutics Development 16
Addex Therapeutics Ltd 16
Aelis Farma S.A.S. 17
Foresee Pharmaceuticals, LLC 18
Grunenthal GmbH 19
Indivior PLC 20
InterveXion Therapeutics LLC 21
P2D Bioscience 22
Zynerba Pharmaceuticals, Inc. 23
Substance (Drug) Abuse - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
2E-2 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ADX-71743 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ADX-88178 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
AEF-0117 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Ch-mAb7F9 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
dronabinol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Enzyme for Cocaine Addiction - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
FP-004 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RBP-8000 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
RO-656570 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Small Molecule to Antagonize Dopamine D1, D2 and D3 Receptors for Cocaine Use Disorder - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Vaccine for Drug Abuse - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Vaccine for Methamphetamine Abuse - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
VU-0463841 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Substance (Drug) Abuse - Recent Pipeline Updates 53
Substance (Drug) Abuse - Dormant Projects 55
Substance (Drug) Abuse - Product Development Milestones 57
Featured News & Press Releases 57
Jan 29, 2015: InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users 57
Jan 05, 2015: InterveXion Therapeutics Receives $5 Million To Support Production Of The Anti-Methamphetamine Monoclonal Antibody 58
Dec 20, 2012: Addex Scientists Discover And Characterize First Potent And Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 Receptor 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Substance (Drug) Abuse, H1 2015 8
Number of Products under Development for Substance (Drug) Abuse - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Substance (Drug) Abuse - Pipeline by Addex Therapeutics Ltd, H1 2015 16
Substance (Drug) Abuse - Pipeline by Aelis Farma S.A.S., H1 2015 17
Substance (Drug) Abuse - Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 18
Substance (Drug) Abuse - Pipeline by Grunenthal GmbH, H1 2015 19
Substance (Drug) Abuse - Pipeline by Indivior PLC, H1 2015 20
Substance (Drug) Abuse - Pipeline by InterveXion Therapeutics LLC, H1 2015 21
Substance (Drug) Abuse - Pipeline by P2D Bioscience, H1 2015 22
Substance (Drug) Abuse - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 32
Substance (Drug) Abuse Therapeutics - Recent Pipeline Updates, H1 2015 53
Substance (Drug) Abuse - Dormant Projects, H1 2015 55
Substance (Drug) Abuse - Dormant Projects (Contd..1), H1 2015 56